Anti-Ny Eso-1 T-Cell Receptor Pbl
Metastatic Melanoma
National Cancer Institute (NCI)Cell therapyPhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
104 Active assets in the Metastatic Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib M.D. Anderson Cancer Center | Phase 2 | BBB |
DACARBAZINE Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Ifa Craig L Slingluff, Jr | Phase 2 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Therapeutic Autologous Lymphocytes Fred Hutchinson Cancer Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Anti-Ny Eso-1 T-Cell Receptor Pbl is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →